Stay updated on Mepolizumab Efficacy in Severe Asthma Clinical Trial

Sign up to get notified when there's something new on the Mepolizumab Efficacy in Severe Asthma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Mepolizumab Efficacy in Severe Asthma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:57:30.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 on the webpage has recently changed to 8, indicating a significant update in the efficacy and safety evaluation of Mepolizumab in severe uncontrolled asthma in Brazil. This change reflects the ongoing efforts to validate external results and assess the impact of new treatments within the Brazilian population.
    Difference
    0.1%
    Check dated 2024-06-06T14:53:32.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying that researchers are looking for individuals 18 years or older with severe eosinophilic asthma and other specific health conditions. Previously, this section had no information provided.
    Difference
    14%
    Check dated 2024-05-22T21:32:44.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:13:33.000Z thumbnail image

Stay in the know with updates to Mepolizumab Efficacy in Severe Asthma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Mepolizumab Efficacy in Severe Asthma Clinical Trial page.